AstraZeneca PLC (AZN.L)

LSE - LSE Delayed Price. Currency in GBp

Add to watchlist

7,167.00-58.00 (-0.80%)

At close: 4:35PM BST

Full screen

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Neutralpattern detected

View all chart patterns

Performance Outlook

Previous Close	7,225.00
Open	7,158.00
Bid	7,176.00 x 0
Ask	7,178.00 x 0
Day's Range	7,146.00 - 7,223.00
52 Week Range	6,736.00 - 10,120.00
Volume	1,617,950
Avg. Volume	3,068,050

Market Cap	94.084B
Beta (5Y Monthly)	0.19
PE Ratio (TTM)	29.42
EPS (TTM)	243.60
Earnings Date	Apr 30, 2021
Forward Dividend & Yield	2.07 (2.87%)
Ex-Dividend Date	Feb 25, 2021
1y Target Est	78.83

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

N/A

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

Editor's Pick
Yahoo Finance Video
We’re not seeing anything that is outside the bounds of what we typically see with new vaccines: Dr. Howard Forman 
Dr. Howard Forman, Yale School of Public Health Professor joins the Yahoo Finance Live panel to discuss the latest with the JNJ vaccine.
- Doctor on J&J vaccine: 'We’re talking about one in a million for these clots'
  Yahoo Finance Video
- How COVID-19 transformed the biotech industry
  Yahoo Finance Video
Editor's Pick
Yahoo Finance Video
Stock market reaction to J&J vaccine pause is ‘pretty modest’: economist
Michael Darda, Chief Economist & Macro Strategist at MKM Partners joins Yahoo Finance Live to discuss the outlook for economic recovery after U.S. regulators called for a pause in the use of Johnson & Johnson’s COVID-19 vaccine.
- J&J vaccines ‘on hold’ in Tarrant after FDA recommends pause over blood clot reports
  Fort Worth Star-Telegram
- European rollout of Johnson & Johnson vaccination delayed after series of clotting cases
  The Telegraph
Reuters
UK trial on switching COVID-19 vaccines adds Moderna and Novavax shots
A UK study into using different COVID-19 vaccines in two-dose inoculations is being expanded to include shots made by Moderna and Novavax, researchers said on Wednesday. The trial, known as the Com-Cov study, was first launched in February to look at whether giving a first dose of one type of COVID-19 shot, and a second dose of another, elicits an immune response that is as good as using two doses of the same vaccine. The idea, said Matthew Snape, the Oxford University professor leading the trial, "is to explore whether the multiple COVID-19 vaccines that are available can be used more flexibly".